ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer. by Wang, Junjian et al.
UC Davis
UC Davis Previously Published Works
Title
ROR-γ drives androgen receptor expression and represents a therapeutic target in 
castration-resistant prostate cancer.
Permalink
https://escholarship.org/uc/item/6dj134h5
Journal
Nature medicine, 22(5)
ISSN
1078-8956
Authors
Wang, Junjian
Zou, June X
Xue, Xiaoqian
et al.
Publication Date
2016-05-01
DOI
10.1038/nm.4070
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
ROR-γ drives androgen receptor expression and represents a 
therapeutic target in castration-resistant prostate cancer
Junjian Wang1, June X. Zou1, Xiaoqian Xue2, Demin Cai1, Yan Zhang2, Zhijian Duan1, 
Qiuping Xiang2, Joy C. Yang3, Maggie C. Louie4, Alexander D. Borowsky5, Allen C. Gao3,8, 
Christopher P. Evans3,8, Kit S. Lam1,8, Jianzhen Xu6, Hsing-Jien Kung1,8, Ronald M. 
Evans7, Yong Xu2, and Hong-Wu Chen1,8
1Department of Biochemistry and Molecular Medicine, School of Medicine, University of 
California, Davis, California, USA
2Institute of Chemical Biology, Guangzhou Institutes of Biomedicine and Health, Chinese 
Academy of Sciences, No. 190 Kaiyuan Avenue, Guangzhou, China
3Department of Urology, School of Medicine, University of California, Davis, California, USA
4Department of Natural Sciences and Mathematics, Dominican University of California, San 
Rafael, California, USA
5Department of Pathology and Laboratory Medicine, School of Medicine, University of California, 
Davis, California, USA
6Shantou University Medical College, No. 22 Xinling Road, Shantou, China
7Gene Expression Laboratory, Salk Institute, Howard Hughes Medical Institute, Salk Institute, La 
Jolla, California, USA
8Comprehensive Cancer Center, School of Medicine, University of California, Davis, Sacramento, 
California, USA
Abstract
The androgen receptor (AR) is overexpressed and hyperactivated in human castration-resistant 
prostate cancer (CRPC). However, the determinants of AR overexpression in CRPC are poorly 
defined. Here we show that retinoid acid receptor-related orphan receptor γ (ROR-γ) is 
overexpressed and amplified in metastatic CRPC tumors, and that ROR-γ drives AR expression in 
the tumors. ROR-γ recruits coactivators SRC-1 and -3 to an AR-RORE to stimulate AR gene 
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transcription. ROR-γ antagonists suppress the expression of AR and its variant AR-V7 in prostate 
cancer (PCa) cell lines and tumors. ROR-γ antagonists also markedly diminish genome-wide AR 
binding, H3K27ac abundance and expression of the AR gene network. Lastly, ROR-γ antagonists 
suppressed tumor growth in multiple AR-expressing but not AR-negative xenograft PCa models, 
and effectively sensitized CRPC tumors to enzalutamide, without overt toxicity in mice. Together, 
these results establish ROR-γ as a key player in CRPC by acting upstream of AR and a potential 
therapeutic target for advanced PCa.
Persistent or reactivated signaling by androgen receptor (AR), a member of the nuclear 
receptor (NR) superfamily, drives progression of prostate cancer to a deadly form of the 
disease, namely metastatic castration-resistant prostate cancer (mCRPC). Tumors in most 
mCRPC patients express abundant AR, regardless of whether the gene encoding AR is 
amplified or mutated1. Recently approved therapeutics such as androgen signaling inhibitor 
enzalutamide (ENZ) and androgen synthesis inhibitor abiraterone (ABI) benefit some 
patients. However, de novo and acquired resistance appears inevitable. In addition to high 
expression of the full-length AR and high intratumoral androgen synthesis, tumor cell 
expression of alternatively spliced variants of AR such as AR-V7 that lack a functional 
ligand binding domain (LBD) constitutes another major resistance mechanism2,3. Current 
therapeutics development is still largely focused on anti-androgens with increased potencies, 
although agents that can disrupt AR N-terminal domain functionality or promote AR protein 
degradation are also being investigated4–9. However, little is known about which factor(s) 
drives AR gene expression in the mCRPC context.
The RAR-related orphan receptors (RORs) ROR-α, -β and -γ (with gene name RORA, 
RORB and RORC respectively) are NRs with distinct tissue expression patterns and likely 
play different physiological functions10,11. T cells express an isoform, ROR-γt encoded by 
RORC2, which differs from ROR-γ in the N-terminus due to T cell-specific promoter usage. 
ROR-γt is essential for differentiation of T cells that produce interleukin 17 (IL-17). 
Aboundant IL-17 promotes autoimmune diseases. As such, multiple ROR-γ antagonists and 
inverse agonists are being developed for therapeutic purposes10,12. Like other RORs, ROR-γ 
binds to specific ROR response elements (ROREs) at its genomic targets likely as monomer 
and can display a constitutive transactivation function in the absence of ligand13,14. ROR-γ-
deficient mice are relatively healthy and fertile15. However, the expression and function of 
ROR-γ in human tumor cells remain largely unexplored.
In this study, we found that ROR-γ is highly overexpressed in tumors from mCRPC 
patients. ROR-γ functions as a key determinant of AR overexpression and aberrant signaling 
in mCRPC tumors. ROR-γ-selective antagonists inhibit AR gene expression, AR genome-
wide binding, and growth of mCRPC cell lines in vitro and in mouse xenografts. Thus, our 
findings establish ROR-γ as a previously unsuspected key player and a novel therapeutic 
target for mCRPC.
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RESULTS
ROR-γ expression and function in metastatic CRPC
Because NRs are attractive therapeutic targets16,17, we reasoned that identification of NRs 
other than AR that play a crucial role in prostate cancer progression may lead to 
development of therapeutics for CRPC. We thus queried gene expression datasets from 
human benign, primary prostate cancer and metastatic prostate cancer samples and searched 
for NRs with altered expression in metastatic compared to benign and primary tumor tissue. 
In both datasets, the expression of ROR-α and ROR-β was significantly lower in metastatic 
tumors when compared to benign prostate tissue or localized tumors; in contrast, the 
expression of ROR-γ was significantly higher in metastatic tumors (Fig. 1a and 
Supplementary Fig. 1a). In addition, the ROR-γ gene RORC was amplified in 6% of 
metastic CRPC tumors in a recent study18 (Supplementary Fig. 1a). Immunohistochemistry 
analysis of benign prostate and prostate tumors revealed that nuclear ROR-γ is 
overexpressed in over 50% of the tumors, and high levels of ROR-γ protein are significantly 
associated with tumor metastasis (Fig. 1b and Supplementary Fig. 1b). ROR-γ protein was 
readily detected by immunoblot in AR-positive cancer cell lines derived from CRPC tumors 
(e.g. LNCaP, C4-2B, 22Rv1, VCaP, PC346C and LAPC4), but not in the non-malignant 
human prostate epithelial cells (RWPE1 and PNT-2) (Fig. 1c).
Next, we examined the function of ROR-γ in prostate cancer. Knockdown of ROR-γ by 
different RORC siRNAs markedly inhibited the growth of LNCaP and its CRPC derivative 
C4-2B cells (Fig. 1d and Supplementary Fig. 1c). The strong growth inhibition was also 
observed in other androgen-sensitive and CRPC models such as VCaP and 22Rv1, but not in 
AR-negative PC-3 cells. ROR-γ knockdown also resulted in induction of apoptosis, as 
demonstrated by the activation of caspase3/7 and cleavage of PARP1, and suppression of 
proteins relevant to oncogenesis, proliferation and survival (e.g. cyclin-A, -E, -D3, Cdc2, 
Cdc6, and Bcl-xL, Myc and ERG (Fig. 1e, f; Supplementary Fig. 1d). Consistent with its 
crucial role in proliferation and survival, ectopic expression of ROR-γ in androgen-sensitive 
LNCaP cells promoted their growth in androgen-deprived conditions (Supplementary Fig. 
1e).
ROR-γ-selective antagonists inhibit CRPC growth and survival
Recent studies identified several ROR-γ-specific antagonists (e.g. SR2211, GSK805, 
XY011/8k; Fig. 2a)19–23. SR2211 and GSK805 have been evaluated for their therapeutic 
potential in suppression of Th17 cell-mediated autoimmune disease models22,24. By 
combining the structural features of SR2211 and GSK805 and structure-based optimization, 
we developed compound XY018 that inhibited ROR-γ constitutive activity in 293T cells 
with high potency (EC50, 190 nM) (Fig. 2a; Supplementary Fig. 2a–d). Molecular docking 
demonstrated that XY018 may bind to the ROR-γ hydrophobic LBD through several 
conserved hydrogen bonds and hydrophobic interactions. For example, the phenyl group in 
the middle likely forms a π-π interaction with the side chain of Phe378 of the LBD, while 
the amide group can form a direct hydrogen bond with Phe377. The nitro group and 
hydroxyl group at the two ends may form hydrogen bonds with Glu379 and His479, 
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respectively. Molecular dynamics simulation demonstrated that the ROR-γ-XY018 complex 
is very stable with these interactions (Supplementary Fig. 2e–f).
Given the crucial function of ROR-γ in prostate cancer cells in vitro, we examined whether 
its antagonists possess any growth-inhibitory effect. All of the ROR-γ antagonists tested 
inhibited PCa cell line growth with higher potency than ENZ (Fig. 2b and Supplementary 
Fig. 3a, b, c). Consistent with our data showing different expression patterns of ROR-α and 
ROR-γ, a ROR-α-selective antagonist SR333525 did not significantly inhibit CRPC cell line 
growth. Moreover, strong growth inhibition by XY018 and SR2211 was observed in other 
AR-positive PCa cell models including 22Rv1, VCaP, LNCaP, LAPC4 and PC346C 
(Supplementary Fig. 3a, b, c). No significant growth inhibition by the ROR-γ antagonists 
was seen in non-malignant human prostate cell RWPE1, normal human fibroblasts IMR90, 
or AR-negative PCa cells at the concentrations tested (Supplementary Fig. 3b, c). Consistent 
with the induction of apoptosis by ROR-γ gene knockdown, treatment of C4-2B and 22Rv1 
cells with XY018 and SR2211 reduced colony formation and increased apoptosis (Fig. 2c–e 
and Supplementary Fig. 3d, e). In line with the cellular effects, XY018 and SR2211 
suppressed the expression of key proliferation and survival proteins, including Myc (Fig. 2f 
and Supplementary Fig. 3f, g).
ROR-γ antagonists inhibit AR signaling
We next analyzed RNA-seq transcriptomes of C4-2B cells treated with the two structurally 
distinct antagonists, SR2211 and XY011, to identify gene programs affected by ROR-γ 
inhibition. Clustering of genes with expression significantly altered by either antagonist 
(relative to vehicle) showed a high degree of concordance in expression changes induced by 
the two ROR-γ inhibitors, with over 75% of genes either decreased (cluster 1) or increased 
(cluster 3) by both antagonists (Fig. 3a). Notably, genes of an AR activity signature derived 
from androgen-sensitive PCa cells and human tumors, which is of value in predicting 
clinical tumor response to androgen ablation therapy26, constitute partly the two major 
clusters (cluster 1 and 3). Genes that are characterized as AR targets or androgen-induced 
genes were significantly inhibited by both antagonists. Conversely, the androgen-repressed 
genes were induced by the ROR-γ antagonists (Fig. 3a). Genes linked to androgen-induced 
cancer cell proliferation and survival were also contained in cluster 1 (e.g. IGF1, RUNX2, 
UHRF1, MCM10, RRM2 and CCNE2) and 3 (e.g. FAS, CDKN1B, DAB2IP and PTEN) 
(Supplementary Fig. 4a). Moreover, the gene expression profiles induced by the antagonists 
significantly overlapped with that of anti-androgen ENZ (41% for SR2211, 38% for XY011 
for down-regulated genes) (Fig. 3a and Supplementary Fig. 4b). Further examination by 
gene set enrichment analysis (GSEA) using the AR activity signature26 revealed a robust 
disruption of AR gene programs by ROR-γ antagonists (Fig. 3b). The ROR-γ antagonists 
also inhibited the expression of genes preferentially up-regulated by AR-V727, and most of 
the genes within the 16-AR target gene set recently identified in human CRPC tumors28 
(Supplementary Fig. 4c, d). qRT-PCR verified that AR gene targets such as KLK3, KLK2, 
NKX3.1, and FKBP5, as well as genes linked to CRPC such as CAMKK229, and ANCCA/
ATAD230 were inhibited by the ROR-γ antagonists and by ROR-γ knockdown (Fig. 3c and 
Supplementary Fig. 4e).
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Inhibition of ROR-γ suppresses AR expression and genome binding
The prominent impact on AR-controlled gene programs by ROR-γ inhibition prompted us to 
investigate whether ROR-γ controls the expression and/or function of AR. Indeed, ROR-γ 
knockdown suppressed the mRNA and protein expression of AR full-length and AR-Vs/7 in 
C4-2B and VCaP cells. The ROR-γ antagonists (XY018, SR2211 and XY011) also 
inhibited the expression of AR and AR-V7 in a dose-dependent manner (Fig. 4a, b and 
Supplementary Fig. 5a, b). Similar dose-dependent inhibition was observed in other AR-
positive cancer cell lines including 22Rv1, LAPC4 and PC346C (Supplementary Fig. 5c). 
Conversely, ROR-γ overexpression significantly increased AR expression in LNCaP cells 
(Supplementary Fig. 5d). Consistent with the results from cell models, in multiple data sets 
from human CRPC tumors, the expression of ROR-γ mRNA correlated strongly not only 
with AR expression but also with a CRPC AR-signature28 (Supplementary Fig. 5e, f).
To assess the ROR-γ antagonist effect on AR function, we performed anti-AR ChIP-seq 
using C4-2B cells treated with 5 µM SR2211 for 24 hours; this caused a significant but 
incomplete suppression of AR expression (Supplementary Fig. 6a). SR2211 treatment 
reduced genome-wide AR binding to its target loci as well as genome-wide abundance of 
histone 3 lysine 27 acetylation (H3K27ac) (Fig. 4c and Supplementary Fig. 6b). AR binding 
at enhancers and/or promoters of targets such as KLK2, KLK3, CAMKK2, NKX3.1, 
FKBP5 and ANCCA/ATAD2 was almost completely eliminated by SR2211 (Fig. 4c, right 
panel and Supplementary Fig. 6c). Similar inhibition of AR binding was also seen with 
antagonist XY018 in ChIP-qPCR analysis (Fig. 4d). In line with the loss of AR occupancy, 
transcriptional activation-linked histone marks including H3K27ac and H3K4me2/3 were 
significantly reduced at KLK3 promoter and enhancer. As expected, RNA polymerase II 
(Pol-II) recruitment at the target promoters was also reduced (Fig. 4e and Supplementary 
Fig. 6d, e). Consistent with the effects of SR2211, knockdown of ROR-γ showed similar 
inhibitory effects on AR binding and associated histone marks (Supplementary Fig. 6f). The 
overall genome-wide distributions of H3K4me2 and H3K4me3 marks as well as Pol-II 
peaks were not markedly affected by SR2211 (Supplementary Fig. 6g), indicating that ROR-
γ inhibition on H4K3me2/3 and Pol-II is target locus-specific.
The ROR-γ-selective antagonists (SR2211, XY018 and XY011) were identified based on 
the unique pocket structure of ROR-γ LBD. Nevertheless, to rule out the possibility that the 
antagonists act directly through AR, we performed a reporter gene assay. In a multimerized 
ARE-driven reporter that can be activated by synthetic androgen R1881 and repressed by 
anti-androgen ENZ, the three ROR-γ antagonists, at up to 10 µM, did not influence R1881-
induced AR activity (Supplementary Fig. 7a). Moreover, molecular docking demonstrated 
that although XY018 could snugly dock into the ROR-γ ligand binding pocket, it simply 
cannot be accommodated by the AR ligand binding pocket due to the relatively short length 
of the pocket (Supplementary Fig. 7b).
To provide further evidence that the ROR-γ antagonists act through suppression of AR 
expression, we performed AR rescue experiments. First, we ectopically expressed a LBD-
truncated form of AR in LNCaP cells and found that the growth inhibition by the antagonists 
was effectively mitigated in the cells while the endogenous AR was suppressed 
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(Supplementary Fig. 7c). Next, we performed a reporter assay with a 5.8 kb KLK3 
regulatory sequence-linked luciferase gene. Results in Supplementary Fig. 7d shows that 
both the androgen-independent and androgen-stimulated activities of endogenous AR were 
strongly inhibited by the ROR-γ antagonists likely due to the suppression of AR expression. 
However, AR ectopic expression effectively blocked the inhibition by the antagonists. In 
contrast, the anti-androgen ENZ was still effective in blocking activity of the ectopic AR. 
Together, our results strongly suggest that the ROR-γ antagonists, acting through ROR-γ, 
effectively suppress the aberrant AR expression and function.
ROR-γ directly controls AR gene expression
The potent inhibition of AR expression by ROR-γ knockdown or antagonists led us to an 
examination whether ROR-γ directly controls AR gene transcription. ROR-γ binds DNA 
with specific sequence motifs AA/TNTAGGTCA (the classic RORE motif) or CT/AG/
AGGNCA (the variant RORE motif)13, 31. In C4-2B cells, ChIP-qPCR of regions containing 
over 20 putative ROREs across the 250 kb AR locus demonstrated that ROR-γ bound to a 
site in the first exon (2.3 kb downstream of AR TSS) (Fig. 5a). The site contains sequences 
matching the variant RORE motif. When cells were treated with the ROR-γ antagonist 
SR2211, ROR-γ binding was reduced (Fig. 5a).
To examine the function of the putative RORE-containing site in mediating ROR-γ 
regulation of the AR gene, we used a lentiviral CRISPR-Cas9 editing system to first delete 
the site with two sets of sgRNAs in C4-2B cells (Fig. 5b, c and Supplementary Fig. 8a). 
Since the dependency of highly elevated AR for the cell proliferation and survival prevented 
us from expanding cell clones with genome editing-reduced AR, we analyzed heterogeneous 
populations of cells, some of which were edited and some of which were likely not. We 
found that even deletion in about half of the cell population (estimated from the PCR 
products of the wild type and deleted alleles in Fig. 5c, left) resulted in a significant 
reduction in the abundance of AR transcripts, which were detected by the upstream primers 
P1 and P2 (Fig. 5d). Next, we treated the editing-heterogeneous cell populations with the 
ROR-γ antagonists and analyzed AR transcripts with primers P3 and P4. As expected, 
abundance of transcripts from the WT allele was reduced by the three antagonists. In 
contrast, in the same samples, transcript levels from the deleted alleles were not significantly 
altered by any of the antagonists (Fig. 5e and Supplementary Fig. 8b), indicating that the site 
is required for ROR-γ antagonist-mediated inhibition of AR transcription. Moreover, as 
expected from the frameshiting effects caused by indels, the three sgRNAs, when used 
singularly, caused a “knock-out” effect on AR protein expression (Supplementary Fig. 8c). 
Importantly, sgRNA-2, the only one that could be designed to cause indel type of alterations 
adjacent to the RORE sequence, also significantly inhibited AR mRNA expression while the 
other two did not (Supplementary Fig. 8c). Finally, we performed reporter gene assays with 
the RORE and found that it was highly responsive to ROR-γ-mediated transactivation. 
Mutations in the core RORE sequence or deletion of ROR-γ C-terminal, AF2 transactivation 
domain completely abrogated the AR-RORE-dependent activation. The three ROR-γ 
antagonists suppressed the activation in a dose-dependent manner (Fig. 5f). Moreover, we 
observed a tight correlation between inhibition of ROR-γ activity (in 293T cells), inhibition 
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of AR expression (in C4-2B) and inhibition of proliferation (in C4-2B) (Supplementary Fig. 
8d, e).
ROR-γ activates gene transcription through association with co-factors such as p160/SRC/
NCoA family members32. Indeed, SRC-1 and SRC-3/ACTR occupied the AR-RORE site. 
Furthermore, their binding was strongly reduced by ROR-γ antagonism or knockdown (Fig. 
5g; Supplementary Fig. 8f), indicating that the SRCs were recruited to the site via ROR-γ. 
Knockdown of SRC-1 and ACTR, but not SRC-2, individually or in combination, decreased 
AR mRNA and protein expression. Treating cells with bufalin, a cardiac glycoside inhibitor 
that was recently shown to selectively degrade SRC-1 and ACTR in cancer cells33, also 
resulted in a dose-dependent inhibition of AR expression (Supplementary Fig. 8g, h). Next, 
we assessed the impact of ROR-γ inhibition on the local chromatin. Treatment with SR2211 
significantly reduced the abundance of the gene activating marks H3K4me3 and H3K27ac at 
the RORE site and AR promoter (Fig. 5g; Supplementary Fig. 8i). Consistent with the 
reduction of AR transcripts, Pol-II occupancy at AR promoter and the RORE site was 
significantly inhibited by ROR-γ inhibition.
ROR-γ antagonists inhibit CRPC tumor growth
We next evaluated the effects of ROR-γ antagonists on prostate cancer tumor growth. Given 
the heterogeneity of PCa, we generated xenografts using PCa cell lines with distinct features 
(e.g. C4-2B which expresses AR with mutated LBD, VCaP with amplified AR gene and 
AR-V7, 22Rv1 which express high levels of multiple AR variants, and AR-negative PC3). In 
mice bearing the three AR-positive tumor models including ENZ-resistant 22Rv1, 5 mg/kg 
intraperitoneal injection of SR2211 (5 times/week when tumors reach approximately 100 
mm3) stopped tumor growth (Fig. 6a, b; Supplementary Fig. 9a). Tumor growth inhibition 
was also observed when using the other antagonists XY018 and XY011 as well as shRNA 
knockdown of ROR-γ in these models (Supplementary Fig. 9b–e). Moreover, in an 
orthotopic model of PCa, treatment with SR2211 suppressed tumor growth (Suppementary 
Fig. 9f–h). In line with a lack of significant effect on the growth of PC3 cells in vitro (Fig. 
2c), SR2211 did not suppress growth of PC3-derived xenograft tumors (Supplementary Fig. 
9i).
Notably, expression of AR and AR targets were markedly inhibited whereas tumor cell 
apoptosis measured by cleaved caspase-3/7 was strongly induced by SR2211 (Fig. 6c). ChIP 
analysis of xenograft tumors showed that SR2211 treatment blocked ROR-γ binding to the 
AR-RORE and AR binding to KLK3 as well as H3K27ac enrichment (Supplementary Fig. 
10). Moreover, in a VCaP-derived mouse model of castration-resistant PCa, the antagonist 
SR2211 alone, at 5 mg/kg, significantly inhibited CRPC tumor growth whereas ENZ alone, 
at 10 mg/kg, did not. Co-administration of the two resulted in persistent suppression of 
tumor growth, indicating that the ROR antagonist can sensitize CRPC tumors to ENZ (Fig. 
6d). As previously reported34,35, VCaP xenograft tumors result in micrometastasis in mice. 
SR2211 treatment inhibited metastasis to the femur and liver (Fig. 6e).
Like ENZ, the ROR-γ antagonists were well tolerated, based on the weight of the animal 
body and vital organs, and their general behavior (Supplementary Fig. 9a–d, 9j, 11a). 
Consistent with ROR-γ being an adipogenesis factor36, the antagonist reduced the amount 
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of the white adipose tissue. Thus, the antagonists can block CRPC tumor growth and 
effectively sensitize tumors to ENZ, without overt toxicity. Interestingly, unlike ENZ, the 
antagonists did not display any discernable effect on the growth of androgen-responsive 
tissues such as mouse prostate and testis or AR expression in the tissue (Supplementary Fig 
11b–d). Analysis of two non-malignant human prostate epithelial cells showed that the 
antagonists did not have any significant effect on endogenous AR expression 
(Supplementary Fig. 12a). To explore the underlying mechanism, we performed ChIP and 
found no detectable ROR-γ binding to the RORE-corresponding site in mouse prostate 
tissue and the two human cell lines (data not shown). Immunoblotting revealed very low 
level of ROR-γ expression in the human cells (Supplementary Fig. 12a). Sequence 
comparsion showed that the corresponding site of mouse AR gene lacks a functional 
RORE13,14(Supplementary Fig. 12b). Together, our results suggest that the ROR-γ 
antagonists can inhibit AR expression specifically in tumor cells and not in nonmalignant 
cells.
DISCUSSION
The most common mechanism driving CRPC development appears to be reactivated AR 
signaling mediated by high levels of AR and its variants in PCa. Therapeutically actionable 
means to effectively suppress AR expression is still lacking. Our study not only 
demonstrates that ROR-γ acts as a key determinant of AR gene expression but also provides 
a unique opportunity for effective therapeutic intervention of CRPC. We found that ROR-γ 
directly stimulates AR gene transcription by binding to an exonic RORE and partly through 
the NR coactivators SRC-1 and SRC-3. Although SRCs and other AR coactivators likely 
play important roles in prostate cancer37–41, they have not been shown to be directly 
involved in AR gene overexpression. We demonstrate here that small molecule antagonists 
of ROR-γ potently disrupt ROR-γ and the SRC binding to the AR locus, reduce the local 
activating histone marks and effectively suppress AR expression in vitro and in vivo. 
Transcription factors such as E2F1, LEF/TCF, and NF-κB can activate AR expression 
whereas others were shown to suppress it42–46. It is possible that ROR-γ also acts in concert 
with them or other factors.
The alternatively spliced variants of AR in tumors treated by anti-androgens and CYP17 
inhibitors (e.g. ENZ and ABI) is linked to therapeutic resistance and metastasis47. Recently, 
agents targeting the AR NTD, an intrinsically unstructured/disordered domain, or enhancing 
degradation of the full-length AR protein are in development5–8. We propose that targeting 
ROR-γ with its selective antagonists effectively inhibits the expression of AR variants such 
as AR-V7 as well as AR full-length, at the gene transcriptional level, therefore mitigating or 
even eliminating the root cause of the problem, namely the highly elevated AR gene 
transcripts and proteins. The ROR-γ antagonists potently inhibited growth of different AR-
positive tumors including those with AR gene amplification and/or high levels of AR 
variants, in mice. Notably, tumors that are resistant to ENZ are sensitive to the antagonists 
(either alone or in combination with ENZ), suggesting that ROR-γ targeting can have a 
broad clinical utility in PCa. The ROR-γ antagonists’ effect on AR expression, instead of on 
AR LBD function, may also offer other therapeutic advantages over anti-androgens. Indeed, 
unlike anti-androgens that suppress the growth and function of normal androgen-responsive 
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tissues such as testis and prostate, the ROR-γ antagonists do not show any significant impact 
on the size of the mouse tissues or AR expression in the tissues and human non-malignant 
prostate cells, because of the lack of ROR-γ function. This tumor-specific effect of the 
antagonists is likely attributable to tumor cell addiction to elevated levels of AR and tumor 
cell-specific control of AR by ROR-γ.
The impact of ROR-γ antagonists on AR gene programs in CRPC cells appears extensive, 
encompassing AR targets that are up-regulated, down-regulated or persistently expressed in 
CRPC tumors28. However, the overall impact on CRPC tumors is unlikely limited to AR and 
its programs. Inflammatory tumor microenvironment is believed to promote CRPC and 
tumor metastasis through production of cytokines such as IL-1748,49. Thus, ROR-γ in 
tumor-inflitrating lymphocytes could play an important role. Therefore, targeting ROR-γ 
can stop tumor growth and metastasis possibly through blocking multiple pathways 
including aberrant AR signaling. As more potent and orally bioavailable ROR-γ antagonists 
are being developed and entering clinical trials for human autoimmune diseases, our findings 
here may have immediate implications on development of a new generation of prostate 
cancer therapeutics.
ONLINE METHODS
Cell culture
LNCaP, C4-2B, 22Rv1, PC-3, and PC346C prostate cancer cells were cultured in 
RPMI1640, VCaP, HEK293T and human fibroblast IMR90 cells were in DMEM, LAPC-4 
was in Iscove’s MEM (all from Corning), and RWPE-1and PZ-HPV-7 were in Keratinocyte 
Serum Free Medium (K-SFM) (Invitrogen) with the supplements. All the culture media 
except for RWPE-1 and PZ-HPV-7 were supplemented with 10% FBS (Hyclone or Gemini) 
except indicated otherwise. For experiments, C4-2B cells were cultured in RPMI 
supplemented with 9% charcoal-dextran-stripped (cds)-FBS plus 1% regular FBS (to mimic 
the CRPC condition) unless indicated otherwise. 22Rv1 cells were cultured in RPMI 
supplemented with 10% cds-FBS. LN/TC-AR cells that inducibly express a C-terminally 
truncated variant of androgen receptor were derived from LNCaP cells as previous 
described50. Cells were grown at 37°C in 5% CO2 incubators. LNCaP, VCaP, 22Rv1, PC-3, 
293T, IMR90, PZ-HPV-7 and RWPE-1 were from ATCC. C4-2B was from UroCor Inc. 
(Oklahoma City, OK). LAPC4 and PC346C were kindly provided respectively by Dr. 
Charles Sawyers (MSKCC, New York) or by Dr. Adrie van Bokhoven (University of 
Colorado). The prostate cancer cell lines were recently authenticated by ATCC using STR 
profiling. Cell lines were regularly tested being negative for mycoplasma.
Chemicals
Sources for chemicals are as follows: SR2211, Calbiochem and TOCRIS; SR1555 and 
SR3335, Cayman. Information on XY018 and XY011 is provided below or described 
before21. Other chemicals are from Sigma unless indicated otherwise.
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qRT-PCR and immunoblotting analysis
Total RNA was isolated from cells in 6-well or 10-cm plates or from xenograft tumors, and 
the cDNA was prepared, amplified and measured in the presence of SYBR as previously51. 
Briefly, the fluorescent values were collected and a melting curve analysis was performed. 
Fold difference was calculated as described previously51. The experiments were performed 
at least three times with data presented as mean values ± s.d. Cell lysates were analyzed by 
immunoblotting with antibodies specifically recognizing ROR-γ, AR, AR-V7 and the 
indicated proteins. The PCR primers and all the antibodies used in this study are described 
in the Supplementary table 1 and 2.
Analysis of ROR mRNA expression, genetic alterations and association with CRPC AR 
signature in clinical tumors
Publicly available prostate cancer expression data sets GSE6919, GSE35988, GSE6811 and 
GSE70768 from previous studies52–55 were downloaded from GEO at http://
www.ncbi.nlm.nih.gov/geo/. The datasets contain gene expression profiles of benign, 
primary, metastatic and/or CRPC tumor samples. Normalized probe set expression for RORs 
were compared between the different tissue/tumor groups by a two-tailed t test for 
significance. Computations were conducted in R statistical package (http://www.r-
project.org/). For genetic alterations of ROR genes, data from a recent genomics study18 at 
cBioPortal for Cancer Genomics (http://www.cbioportal.org) was interrogated and 
OncoPrint displays of gene alterations were presented. Expression correlation between 
ROR-γ and AR in tumors was assessed by computing the Pearson correlation coefficient (r) 
and a two-tailed t test for significance. For correlation between ROR-γ and the AR signature 
activity, the expression of the 150 CRPC AR-signature genes28 is summarized as a single 
expression profile as previous reported56 before applied to computation of the Pearson 
correlation statistics.
Immunohistochemistry (IHC) and statistics analysis
IHC was performed as previously described51,57 with the following modifications. Antigen 
retrival for sections of tissue microarrays (TMA PR803b from Biomax.US) was performed 
in a pressure cooker. The slides were then incubated with anti-ROR-γ monoclonal antibody 
(AFKJS-9, eBioscience) at 1:50 dilutions overnight at 4°C, followed by incubations with 
biotinylated secondary antibody and the ABC reagents in the Vectastain Elite kit and 
counter-stained with hematoxylin. The TMA contained specimens from 70 cases of prostate 
cancer with information provided for most of the cases on stage, Gleason scores and TNM 
grading. The percentage of positive nuclear staining was scored as follows: 0% – <5%, score 
0; 5% – <10%, score 1; 10% – 50%, score 2; >50%, score 3. Differences and correlations in 
immunostaining among groups were analyzed with the χ2 test.
Cell viability, apoptosis and growth assays, and colony formation
For cell viability, cells were seeded in 96-well plates at 1500–2500 cells per well (optimum 
density for growth) in a total volume of 100µl media. Serially diluted compounds in 100µl of 
media were added to the cells 12 hours later. After 4 days of incubation, Cell-Titer GLO 
reagents (Promega) were added and luminescence was measured on GLOMAX microplate 
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luminometer (Promega), according to the manufacturer’s instructions. All experimental 
points were set up as sextuplicate as biological replication and the entire experiments were 
repeated three times. The data are presented as percentage of viable cells with vehicle 
treated cells set as 100. The estimated in vitro IC50 values were calculated using GraphPad 
Prism 6 software.
For apoptosis, Terminal deoxynucleotidyl transferase–mediated dUTP nick end labeling 
(TUNEL) was performed by using in situ cell death detection kit (Roche) as previously 
described57. The results are expressed as a percentage of apoptotic cell number/total cell 
number. Caspase-3/7 activity was measured using a luminescent caspase-Glo 3/7 assay kit 
(Promega Corporation, Madison, USA) following the manufacturer's instructions. For cell 
growth, cells were seeded in 6-well plates at 2 × 105 per well and treated as indicated. Total 
viable cell numbers were counted using a Coulter cell counter. For colony formation, 800 
cells were seeded in a well of 6-well plates and cultured for 14 days with the medium 
changed every 3 days. When the cell clone grew visible, the medium was removed and the 
cells were fixed with 10% formalin for 10 minutes. Then the plates were washed with PBS 
for two times and the cell colonies were stained with 0.2% crystal violet (in 10% formalin) 
for 15 minutes. The numbers of cell colonies were counted after washed 5 times by PBS. 
The above assays were performed in triplicates and the entire experiments were repeated 
three times.
ROR-γ shRNA and overexpression lentivirus production and siRNA transfection
Lentiviral plasmids encoding shRNA targeting ROR-γ/RORC (TRCN0000033655 and 
TRCN0000033658) were purchased from Sigma. Non-targeting control shRNA were used 
as described51. For ROR-γ overexpression, human ROR-γ cDNA in pLX304 (DNASU) was 
amplified and cloned into a modified pLX304 vector with a V5 tag at the receptor N 
terminus. Lentiviral particles were produced in 293T cells after co-transfection of the above 
lentivirus vectors, psPAX2 and pMD2.G in 10 cm dishes, as described51. siRNAs for gene 
knockdown were purchased from Dharmacon. The siRNA target sequences for ROR-γ and 
different SRCs are listed in supplementary table 3. Transfections were performed with 
OptiMEM (Invitrogen) and Dharmafectin#1 (Dharmacon) following manufacturer’s 
instruction.
Reporter constructs and reporter gene assays
Transient transfection and reporter gene assays were performed as previously described51 
with following modifications. ARE reporter gene assays were performed by transfecting 
22Rv1 cells with 5 × ARE-tk-luc, pcDNA3.1-hAR and pCMV-β-gal for normalization. For 
transfection with constructs omitted for specific gene expression, corresponding empty 
vectors were used to ensure equal amount of total DNA used. Briefly, 22Rv1 cells seeded in 
96- well plates in hormone-deprived medium supplemented with 10% cds-FBS (Hyclone) 
were transfected with lipofectamine 2000 (Life technology, Carlsbad, CA, USA) and the 
indicated plasmid DNA. Cells were then treated at 12 hours after transfection with 3 nm 
R1881, indicated concentrations of ROR-γ antagonists or ENZ for another 24 hours before 
harvested for β-gal and luciferase assays. For RORE reporter gene assays, 4 × AR-RORE-tk-
luc was constructed by inserting four copies of the newly identified AR-RORE 
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TTCTGGGTCA into tk-luciferase reporter vector. AR-RORE mutant form (AR-RORE mut) 
contains sequences mutated from TTCTGGGTCA to TTCTGAACGA. Cells (HEK293T) 
were co-transfected with CMX-ROR-γ or CMX-ROR-γΔH12 expression vector and the 
RORE-tk-luc reporter plasmid as indicated using Lipofectamine 2000 (Life technology, 
Carlsbad, CA, USA). After 12 h incubation, cells were treated with vehicle or ROR-γ 
antagonists as indicated for another 24 hours. For Gal4-driven reporter assays, 293T cells 
were transfected with Gal4-ROR-γ LBD and pGL5-luc reporter. The luciferase and β-
galactosidase were then analyzed with a Luciferase Assay Substrate (Promega) and 
Luminescent β-galactosidase Detection Kit II (Clontech). All transfections were performed 
in triplicate, and each experiment was repeated at least three times.
CRISPR/Cas9 sgRNA design, lentivirus production and PCR-based assay to detect 
genomic deletions
sgRNAs were designed using the MIT CRISPR design software (http://crispr.mit.edu). 
Oligos corresponding to the sgRNAs were synthesized and cloned into lentiCRISPR v2 
vectors following lentiCRISPRv2 and lentiGuide oligo cloning protocol (Addgene, 
plasmid#52961). sgRNA sequences are as follows: GFP: GGGCGAGGAGCTGTTCACCG; 
AR-RORE#1: CTGGCGAGCCTGCATGGCGC; AR-RORE#2: 
GTGCAGCGGGACCCGGTTCT; AR-RORE#3: ACTCTCTTCACAGCCGAAGA. 
Lentiviral particles were produced in 293T cells as described above. C4-2B cells were plated 
at 2 × 105 cells per well in 6-well plates. Sixteen hours later, 1 ml of virus-containing 
supernatant with 10 ng polybrene was added to the cells. After 4 to 6 hours, medium was 
changed to regular medium and cultured for another 72 hours. Genomic DNA was isolated 
from cells using the PureLink Genomic DNA kit (Life technology). PCR was performed 
using indicated primers flanking the sgRNA target sites. PCR products from deleted alleles 
were purified by running agarose gel and were ligated into plasmids using pGEM-T Easy 
Vector Systems (Promega). Plasmid DNA was purified from single bacterial colonies by 
mini-prep kit (Qiagen) and sequenced by GENEWIZ (Davis, California) using Sanger 
sequencing method.
Analysis of AR mRNA expression in cells treated with CRISPR/Cas9-sgRNA lentivirus
Cells were infected with the CRISPR/Cas9 sgRNA lentiviruses as above and cultured for 2 
days. ROR-γ antagonists or vehicle were then added and cells were cultured for another 2 
days. Total RNA was extracted by TRIzol and reverse transcribed. Semi-quantitative RT-
PCR was performed using the template cDNA generated and indicated primers. PCR 
products were separated on agarose gels. Quantification of the bands was performed as 
previously reported58. Band intensity was expressed as relative absorbance units and 
normalized to GAPDH.
RNA-seq data analysis
C4-2B cells were treated with vehicle or the antagonists XY011 (5 µM) and SR2211 (5 µM) 
or ENZ (20 µM) for 48 hours before RNA extraction. RNA-seq libraries from 1µg total RNA 
were prepared using Illumina Tru-Seq RNA Sample, according to the manufacturer’s 
instructions. Libraries were validated with an Agilent Bioanalyzer (Agilent Technologies, 
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Palo Alto, CA). Sequencing was performed on an Illumina HiSeq 2000 sequencer at BGI 
Tech (Hong Kong). The FASTQ-formatted sequence data were analyzed using a standard 
BWA-Bowtie-Cufflinks workflow59–61. In brief, sequence reads were mapped to the 
reference human genome assembly (Feb. 2009,GRCh37/hg19) with BWA and Bowtie 
software. Subsequently, the Cufflinks package62 was applied for transcript assembly, 
quantification of normalized gene and isoform expression in RPKM (Reads per kilobase per 
million mapped reads) or FPKM (fragments per kilobase of exon model per million mapped 
reads), and testing for differential expression (Cuffdiff). To avoid spurious fold levels due to 
low expression values, only those genes with expression RPKM or FPKM values > 1 for 
either the vehicle/control cell, or the antagonist treated cells (but need not to be both), are 
included. The expression change of at least 1.5 fold up or down was clustered with K-mean 
clustering algorithm in Cluster software63. The cluster was displayed with TreeView.
GSEA analysis
GSEA was performed using the Java desktop software (http://www.broadinstitute.org/gsea) 
as described previously64. Genes were ranked according to the shrunken limma log2 fold 
changes and the GSEA tool was used in 'pre-ranked' mode with all default parameters. 
Previous reported AR activity signature genes26 were used in the GSEA analysis.
ChIP-qPCR analysis
ChIP-qPCR analysis was performed as described previously51. The antibodies used for ChIP 
assay are AR (Santa Cruz; sc-815); RNA Pol-II (Santa cruz; sc-899); H3K4me2 (Abcam 
ab32356); H3K4me3 (Abcam; ab8580); H3K27ac (Abcam; ab4729); H3 (Active Motif; 
#39163); p300 (Santa Cruz; sc-585); SRC-1 (Santa Cruz; sc-8995); SRC-3/ACTR65, and 
IgG (Santa Cruz; sc-2027). Anti-RORγ rabbit serum was generated by Covance using 
purified GST-human RORγ fragment (amino acids 79–301) expressed in E.coli. PCR 
primers used in the ChIP assays were listed in the Supplementary table 2. ChIPs were 
performed with each experimental point in triplicate, and each experiment was repeated 
three times.
ChIP-seq and data analysis
C4-2B cells were treated with vehicle or SR2211 (5 µM) for 24 hours before harvested for 
ChIP-seq. ChIP-seq experiments were performed as described66. Anti-AR ChIP-seq was 
repeated in two independent experiments. Antibodies used were against AR (Santa Cruz; 
sc-815); RNA Pol II (Santa cruz; sc-899); H3K4me2 (Abcam ab32356); H3K4me3 (Abcam; 
ab8580); H3(acetyl K27) (Abcam; ab4729). Libraries were quantified with the Bioanalyzer 
2100 (Agilent) and sequenced on the Illumina HiSeq 2000 Sequencer (BGI, Hong Kong). 
Sequencing tags were mapped against the Homo sapiens (Human) reference genome (hg19) 
using Bowtie 267. Uuniquely mapped tags were used for peak calling by MACS(2.1.0)68 to 
identify regions of ChIP-Seq enrichment over background. A q value threshold of 
enrichment of 5 × 10−2 was used for all data sets. Normalized genome-wide signal coverage 
tracks from raw read alignment files were built by MACS2, UCSC tools (http://
hgdownload.cse.ucsc.edu/admin/exe/linux.x86_64/bedGraphToBigWig/bedClip) and 
bedTools (http://code.google.com/p/bedtools/). Visualization of ChIP-seq singnal at enriched 
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genomic regions(avgprof and heatmap) was achieved by using ngs.plot (https://github.com/
shenlab-sinai/ngsplot).
Xenograft tumor models and chemical compound treatments
Four-week-old male SCID C.B17 mice (for C4-2B and VCaP) or BALB/c nu/nu athymic 
mice (for 22Rv1 and PC-3) were purchased from Harlan Inc. For establishing tumors, 2 × 
106 cells were suspended in total of 100 µL PBS/Matrigel (1:1) and implanted 
subcutaneously into the dorsal flank on both sides of the mice. Animal group size of six or 
more was estimated to have a high statistic power, based on power calculation (http://
www.biomath.info/power/) and previous studies involving the same xenograft models34,69. 
When the tumor volume was approximately 80 mm3, the mice were randomized and then 
treated intraperitoneally (i.p.) with 100 µl of either vehicle or ROR-γ antagonists SR2211, 
XY018 or XY011/8K (in a formulation of 15% Cremophor EL, Calbiochem, 82.5% PBS, 
and 2.5% DMSO) for five times per week. Tumor growth was monitored by calipers with 
volume calculated using the equation: (π/6 (length × width2)). Body weight during the 
course of the study was also monitored. At the end of the studies mice were killed and 
tumors were dissected and weighed. Additionally, prostate, seminal vesicle, testis, kidney, 
heart, lung, liver, epididymal fat pad and spleen were harvested and weighed. To assess the 
effect of combining ROR-γ antagonists and ENZ on the growth of castrated-resistant VCaP 
xenografts (CRPC-VCaP), first, SCID C.B17 mice were injected with VCaP cells as above 
to establish the tumors. Then, mice bearing tumors of approximately 180 mm3 were 
surgically castrated. They were then observed for tumor regression. Once tumors grew back 
to the pre-castration size, mice were randomized and treated with vehicle, 5 mg kg−1 
SR2211, 10 mg kg−1 ENZ or a combination of 5 mg kg−1 SR2211 and 10 mg kg−1 ENZ. 
ENZ was given by oral gavage as previously described69 and SR2211 was administered i.p 
as above. Mice were exluded from the study if bearing no tumor or tumor with size twice 
larger or smaller than the mean, at the time of randomization.
To assess the effect of ROR-γ antagonists on the growth of orthotopic prostate tumors, C4-2 
cells suspended in Matrigel as above were injected orthotopically into SCID C.B17 mice. To 
monitor tumor growth, mice were bled and serum PSA levels were measured using PSA 
(human) ELISA kit (Abnova). When serum PSA were detectable, the mice were randomized 
into different groups for the treatment. To assess the effect of ROR-γ knock down on tumor 
growth, C4-2B cells infected with lentivirus encoding control shRNA or shRNA targeting 
ROR-γ were injected subcutaneously into both sides of the dorsal flank of mice. Tumor 
growth was monitored weekly by calipers. Tumor volumes were measured in a blinded 
fashion (to treatment groups). The procedures were approved by the Institutional Animal 
Care and Use Committee of University of California Davis.
Statistical Analysis
Cell culture-based experiments were performed three times or more with assay points 
triplicated or sextuplicated, as indicated. The data are presented as mean values ± s.d. from 
three independent experiments. Statistics analysis was performed using two-tailed Student’s 
t tests to compare means. p < 0.05 was considered significant.
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Molecular docking & molecular dynamics simulation
Schrödinger 2014 Suite was used to predict the potential binding mode of ROR-γand its 
ligands. The crystal structure of ROR-γ LBD in complex with antagonist (PDB code: 
4QM0.pdb) was used as the reference structure in the docking study. Protein structure 
preparation for docking studies included water deletion, hydrogen atom addition and 
protonation state adjustment. All of the ligand and protein preparation were performed in 
Maestro (version 9.9, Schrödinger, LLC, New York, NY, 2014) implemented in the 
Schrödinger program (http://www.schrödinger.com). In this study, ligands were prepared 
using the Ligprep module to obtain energy minimized 3D structures, which were then 
docked into ligand binding pocket with the Glide molecular docking program (version 6.4, 
Schrödinger, LLC, New York, NY, 2014) using the Glide SP, and Glide XP modes. For all of 
the methods, Glide docks flexible ligands into a rigid receptor structure. Final ranking from 
the docking was based on the docking score, which combines the Epik state penalty with the 
Glide Score. Finally, the binding poses with the top glide score (20 poses) were clustered 
and selected for further visual evaluation and molecular dynamics simulations.
Molecular dynamics (MD) simulations were conducted by using AMBER 14 program. The 
starting coordinates were obtained from docking results. For ligand coordinates, top scored 
representative poses of each cluster were chosen. For protein coordinates, the protein 
preparation panel in Schrodinger 2014 Suite was applied to assign the protonation states and 
orientations of residues, which was then further processed by using LEaP module in Amber 
program. Parameters of compounds were prepared by AM1-bcc model and the other 
parameters were assigned from the AMBER GAFF force field using ANTECHAMBER. 
Topology and parameter files for the protein, ligand and complex were generated using the 
LEaP module in AMBER 14. TIP3PBOX water molecules were added in cube periodic 
boxes, which were 10 Å × 10 Å × 10 Å. To ensure overall neutrality of the system, 
appropriate Na+ and Cl− were added at physiological concentration in the box. For each 
system, energy minimization and MD simulation were carried out using the GPU version of 
the PMEMD program in AMBER 14 program. The MD simulations were performed for up 
to 200 ns for each complex system. The coordinates of the complexes were saved every 2 ps, 
those snapshots were taken in production run for detailed analysis. Trajectories were 
analyzed using the PTRAJ module in Amber 14.
AlphaScreen Assay
The human ROR-γ LBD (residues 262–507) was expressed as a His6-fusion protein using 
the pET24a expression vector (Novagen, Madison, WI) as described in reference11. 
Interactions between ROR-γ and ligands were assessed by luminescence-based AlphaScreen 
technology (Perkin Elmer) using a histidine detection kit from PerkinElmer (Norwalk, CT). 
All of the reactions contained 100 nM receptor LBD bound to nickel acceptor beads (5 
µg/mL) and 20 nM biotinylated SRC1-4 peptide bound to streptavidin donor beads (5 
µg/mL) in the presence or absence of the indicated amounts of control compounds SR2211 
or candidate compounds. The N-terminal biotinylated coactivator peptide SRC1-4 sequence 
was QKPTSGPQTPQAQQKSLLQQLLTE. Compound concentrations varied from 150 nM 
to 200 µM in the dose-response assay.
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Thermal Shift Assay
All reactions were carried out using a CFX96 real-time PCR system (Bio-Rad). Protein were 
buffered in 10 mM of HEPES, pH 7.5, 150 mM of NaCl and 5% glycerol at a concentration 
of 7.5 µM. Compounds were added at a final concentration of 200 µM. All assays were set 
up in 20 µL final reaction volume in 96-well plate with 10× SYPRO Orange (Invitrogen) and 
incubated with compounds on ice for 30 mins. The samples were heated from 30 °C to 
90 °C with a thermal ramping rate of 1 °C/min and the fluorescence signals were read out. 
ΔTm was recorded as the difference between the transition midpoints of sample and 
reference wells containing protein without ligand in the same plate.
Synthesis of N-(2'-fluoro-4'-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl) -[1,1'-biphenyl]-4-
yl)-2-(2-nitrophenyl)acetamide(XY018)
Reagents and solvents were obtained from commercial suppliers and used without further 
purification. Flash chromatography was performed using silica gel (300–400 mesh). All 
reactions were monitored by TLC, using silica gel plates with fluorescence F254 and UV 
light visualization.1H-NMR spectra were recorded on a Bruker AV-400 spectrometer at 400 
MHz. Coupling constants (J) are expressed in hertz (Hz). Chemical shifts (δ) of NMR are 
reported in parts per million (ppm) units relative to internal control (TMS). The low- or 
high-resolution of ESI-MS was recorded on an Agilent 1200 HPLC-MSD mass spectrometer 
or Applied Biosystems Q-STAR Elite ESI-LC-MS/MS mass spectrometer, respectively.
To 2-fluoroaniline (6g, 54 mmol) in a pressure vessel was added hexafluoroacetone 
trihydrate (12.5 g, 56.7 mmol) and p-toluenelsuphonic acid (0.85 g, 5.4 mmol). The reaction 
mixture was stirred at 90°C for 12 hrs. After water was added, it was extracted with ethyl 
acetate and the organic layer was washed with saturated NaHCO3solution and brine and 
dried over Na2SO4. The solid was filtered off and the filtrate was concentrated under 
reduced pressure. The resulting crude product was purified by silica gel chromatography 
with petroleum ether/ethyl acetate (10/1, v/v) to yield 2-(4-Amino-3-
fluorophenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol as white solid (4.45 g, 30 % yield).MS 
(ESI), m/z for C9H6F7NO ([M+1]+): Calcd 277.14, found 278.0.
To a solution of 2-(4-amino-3-fluorophenyl)-1,1,1,3,3,3-hexafluoro propan-2-ol (4.45 g, 
16.1 mmol) in DMF (100mL) was added concentrated HCl (18 mL, 73 mmol) and sodium 
nitrite (1.66 g, 24 mmol), dissolved in H2O (20 mL) at 0 °C. The reaction mixture was 
stirred at 0°C for 30 min. Then potassium iodide (4 g, 24 mmol) was added in portions. The 
mixture was stirred at room temperature for overnight. Added ethyl acetate, washed with a 
saturated NaHCO3solution and brine and dried over Na2SO4. The solid was filtered off, and 
the filtrate was concentrated under reduced pressure. The resulting crude product was 
purified by silica gel chromatography with petroleum ether/ethyl acetate (50/1, v/v) to yield 
1,1,1,3,3,3-hexafluoro-2-(3-fluoro-4-iodophenyl)propan-2-ol (6.2 g, 96 % yield). 1HNMR: 
(400 MHz, d-DMSO) δ 7.31 (d, J = 8.4 Hz, 1H), 7.48 (d, J = 1.6 Hz, 9.2 Hz, 1H), 8.05 (dd, 
J = 6.8 Hz, 8.4 Hz, 1H), 9.07 (s, 1H).
To a solution of 1,1,1,3,3,3-hexafluoro-2-(3-fluoro-4-iodophenyl) propan-2-ol (6.2 g, 16 
mmol) in 1,4-dioxane (100 mL) and water (20 mL) was added (4-((tert-
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butoxycarbonyl)amino)phenyl)boronic acid (4.2 g, 17.6 mmol), followed by addition of 
potassium carbonate (6.6 g, 48 mmol) and Pd(PPh3)4(0.9 g, 0.78 mmol), the vessel was 
purged with argon, sealed and heated to 80°C for 5 hrs. Added water, extracted with ethyl 
acetate, the organic layer was washed with brine and dried over Na2SO4. The solid was 
filtered off, and the filtrate was concentrated under reduced pressure. The resulting crude 
product was purified by silica gel chromatography with petroleum ether/ethyl acetate (20/1, 
v/v) to yield tert-butyl(2'-fluoro-4'-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-[1,1'-
biphenyl]-4-yl)carbamate (5.35 g, 74 % yield). 1H NMR (400 MHz, CDCl3) δ 7.54 –7.44 
(m, 6H), 7.40 (d, J = 8.4 Hz, 1H), 6.57 (s, 1H), 3.82 (s, 1H), 1.53 (d, J = 3.2 Hz, 9H).
To a solution of tert-butyl (2'-fluoro-4'-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan -2-yl)-[1,1'-
biphenyl]-4-yl)carbamate (5.35 g, 11.8 mmol) in DCM (50 mL) was added trifluoroacetic 
acid (7 mL, 96 mmol) dropwise at 0 °C. The reaction mixture was stirred at room 
temperature for 3 hrs and then concentrated under reduced pressure. Recrystallisation was 
then carried out in petroleum ether and ethyl acetate and 2-(4'-amino-2-fluoro-[1,1'-
biphenyl]-4-yl)-1,1,1,3,3,3-hexafluoro propan-2-ol was isolated (3.8 g, 91% yield). 1H NMR 
(400 MHz, d-DMSO) δ 8.91 (s, 1H), 7.61 (t, J = 8.4 Hz, 1H), 7.50 – 7.47 (m, 2H), 7.30 (d, J 
= 7.2 Hz, 2H), 6.65 (d, J = 8.4 Hz, 2H), 5.41 (s, 2H).
To a solution of 2-(2-nitrophenyl) acetic acid (56 mg, 0.31 mmol) in DCM (20 mL) was 
added HATU (213 mg, 0.56 mmol) and DIPEA (0.5 mL). The mixture was stirred at room 
temperature for 5 min, then added 2-(4'-amino-2-fluoro-[1,1'- biphenyl]-4-yl)-1,1,1,3,3,3-
hexafluoro propan-2-ol (100 mg, 0.28 mmol). The reaction mixture was stirred at room 
temperature for 3 h. Added water, extracted with ethyl acetate, the organic layer was washed 
with brine and dried over Na2SO4. The solid was filtered off and the filtrate was 
concentrated under reduced pressure. The resulting crude product was purified by silica gel 
chromatography with petroleum ether/ethyl acetate (4/1, v/v) to yield N-(2'-fluoro-4'-
(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-[1,1'-biphenyl]-4-yl)-2-(2-
nitrophenyl)acetamide (118 mg, 81% yield). 1H NMR (400 MHz, CDCl3) δ 8.09 (d, J = 
8.4Hz, 1H), 7.94 (s, 1H), 7.66 (t, J = 7.6 Hz, 1H), 7.61 – 7.46 (m, 9H), 4.26 (s, 1H), 4.03 (s, 
2H). MS (ESI), m/z for C23H15F7N2O4 ([M+1]+): Calcd 516.37, found 517.0.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. ROR-γ overexpression associates with metastatic CRPC progression and is required 
for survival of prostate cancer cells
(a) RORC transcript levels from two GEO datasets were queried for association with disease 
status (benign, primary and metastatic). p values were calculated using two tail t-test. Box 
plot line (from top to bottom): maximum, Q3, Median, Q1 and minimum, where Q1 and Q3 
are the first and third quartile respectively.
(b) Representative images from ROR-γ IHC of normal prostate (n = 8) or a cohort of 
prostate cancer tumor specimens (n = 70). Scale bars, 50 µm.
(c) Immunoblotting analysis of ROR-γ protein in prostate cancer and non-cancer cell lines. 
Shown are representative blot, n = 4.
(d) C4-2B (left) in 9% charcoal-dextrand-stripped (cds) FBS plus 1% FBS medium and 
VCaP (right) in regular FBS medium were transfected with RORC or control siRNA. After 
indicated times, viable cells were counted. Data shown are mean ± s.d. Student’s t-test. ** p 
< 0.001, n = 3.
(e) C4-2B cells were treated as in (d) and apoptosis was analyzed by measuring caspase3/7 
activity. Data shown are mean ± s.d. Student’s t-test. ** p < 0.001, n = 3.
(f) Immunobloting analysis of indicated proteins in C4-2B and VCaP cells transfected with 
RORC or control siRNA and incubated for three days. Shown are representative blot, n = 3.
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Figure 2. ROR-γ antagonists inhibit growth of CRPC cells
(a) Chemical structures of ROR-γ antagonists SR2211, XY018 and XY011.
(b) Cell viability measured by Cell-Titer GLO of C4-2B cells treated with indicated 
concentrations of enzalutamide (ENZ), ROR-α agonist SR3335 and ROR-γ antagonists 
XY018, SR2211, XY011 and SR1555 for 4 days. Experiments were performed with three 
independent experiments and sextuplicate.
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(c) C4-2B and 22Rv1 cells were treated with vehicle or indicated concentrations of SR2211 
or XY108 or XY011 for 14 days and colony formation was assessed. * p < 0.05, ** p < 
0.01, n = 3.
(d) Caspase-3/7 activities in C4-2B and 22Rv1 cells treated with vehicle or indicated ROR-γ 
antagonists for 3 days. ** p < 0.01, n = 3.
(e) TUNEL-positive apoptotic cells treated with vehicle or ROR-γ antagonists (5 µM) were 
counted and expressed as percentage of total cells. Data shown are mean percentage of 
apoptotic cells ± s.d. * p < 0.05, ** p < 0.01, n = 3.
(f) Immunoblotting analysis of indicated proteins in C4-2B cells treated with vehicle or 
indicated ROR-γ antagonists for 3 days. Representative blots, n = 3.
All data shown above are mean ± s.d. Significance was calculated using Student’s t-test.
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Figure 3. ROR-γ controls AR-dependent gene programs
(a) Heatmap displaying the fold changes of gene expression detected by RNA-seq in C4-2B 
cells treated with either SR2211 (5 µM), XY011 (5 µM) or ENZ (20 µM) for 48 hours, 
compared to vehicle. Left, genes that were altered in expression with log2 > 0.5 in at least 
one condition are displayed. Cluster 1, genes inhibited by both antagonists; cluster 2, genes 
induced by SR2211 but inhibited by XY011; cluster 3, genes induced by both antagonists; 
cluster 4, genes inhibited by SR2211 but induced by XY011. Middle and right, androgen-
responsive, AR activity signature genes that were altered in expression are displayed, with 
Wang et al. Page 25
Nat Med. Author manuscript; available in PMC 2016 November 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
AR target genes in light blue which were defined by AR ChIP-seq peaks, and genes that 
were also affected by ENZ are also displayed for comparision.
(b) GSEA of the AR activity signature in C4-2B cells treated with 5 µM SR2211 (up) or 
XY011 (down) compared to vehicle. The signature was defined by genes with significant 
expression changes by androgen stimulation in PCa cells and androgen deprivation in human 
tumors26.
(c) qRT-PCR analysis of indicated genes in C4-2B cells treated with vehicle or ROR-γ 
antagonists (5 µM) for 48 hours. Data shown are mean ± s.d. Student’s t-test. ** p < 0.001, n 
= 3.
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Figure 4. ROR-γ inhibition strongly suppresses AR and its variant expression and eliminates AR 
genome binding
(a) Immunoblotting of AR (full length) and AR variants in C4-2B or AR-V7 in VCaP cells 
treated with control or ROR-γ siRNAs, or with ROR-γ antagonists at indicated 
concentrations for 72 hours. Representative blots, n = 4.
(b) qRT-PCR analysis of AR full-length and AR-V7 expression in VCaP cells treated with 
vehicle, 5 µM XY018 or SR2211 for 48 hours. ** p < 0.01, n = 3.
(c) ChIP-seq summary plot of AR enrichment (average coverage; left) across AR-binding 
sites (ARBS) and H3K27ac enrichment (middle) across the indicated genomic distance in 
different treatments. Right, genome browser display of AR binding and H3K27ac 
enrichment events on enhancers and/or promoters of AR target genes KLK2, KLK3 and 
CAMKK2. ChIP-seq was performed in C4-2B cells treated with vehicle or SR2211 (5 µM) 
for 24 hours.
(d) And (e) ChIP-qPCR analysis of relative AR, p300 and Pol II occupancy, or histone 
modifications at indicated gene promoter and/or enhancer in C4-2B cells treated with 
vehicle or 5 µM of XY018 or SR2211 for 24 hours. * p < 0.05, ** p < 0.01, n = 3.
Data shown above are mean ± s.d. Significance was calculated using Student’s t-test.
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Figure 5. ROR-γ directly controls AR gene expression through an exonic RORE and SRCs
(a) Left, schematics of AR gene locus with ChIP primer-pair locations indicated by 
horizontal short lines and their distance in kb relative to TSS. The primer pair amplifying the 
RORE site is in red. Right, ChIP-qPCR analysis of ROR-γ occupancy at the locus in C4-2B 
cells treated with vehicle or 5µM SR2211. n = 3.
(b) Schematic diagram depicting the locations of gRNAs targeting the AR-RORE region, 
primers used for genomic DNA PCR or RT-PCR and predicted Cas9 cleavage sites (red 
arrow head). Note: due to the lack of additional PAM sequence at or near the RORE, 
sgRNA-2 is the only one that can be designed to cause indel type of alterations adjacent to 
the RORE sequence.
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(c) PCR and sequencing analysis of genomic DNA from editing-heterogenous C4-2B cells 
treated with indicated sgRNAs and Cas9. Genomic DNA PCR was performed using primers 
p3 and p4. The top band indicates the expected full-length PCR amplicons. The two lower 
bands indicate the expected PCR amplicons with deletions caused by the indicated sgRNA-
guided editing. PCR products containing the deletion amplicons were cloned and sequenced. 
Representative sequencing chromatograms of expected deletion junctions are shown, n = 
25). Red arrowheads indicates expected deletion junction.
(d) qRT-PCR analysis with primers p1 and p2 of AR mRNA in C4-2B cells treated with 
indicated sgRNAs. ** p < 0.01, n = 3.
(e) Semi-quantitative RT-PCR analysis with primers p3 and p4 of AR mRNA in C4-2B cells 
treated with indicated sgRNAs and ROR-γ antagonists (5µM, 48 hours), as illustrated at left, 
for measuring effects of the antagonists on AR mRNA expression from wild type or deleted 
alleles. Representative gel images are shown, n = 3.
(f) Sequences of the wild type (in purple) and mutated (in blue) form of AR-RORE linked to 
reporters (top). AR-RORE reporter gene assays with 293T cells showing effects of mutating 
the RORE sequence or ROR-γ (left), or the antagonists (right) on ROR-γ activation. ** p < 
0.01, n = 3.
(g) ChIP-qPCR analysis of relative occupancy by indicated proteins at the AR-RORE site in 
C4-2B cells treated with vehicle or 5µM SR2211 for 24 hours. * p < 0.05, ** p < 0.01, n = 3.
Data shown are mean ± s.d. Significance was calculated using Student’s t-test.
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Figure 6. ROR-γ antagonists potently inhibit tumor growth and metastasis
(a) and (b) Effects of indicated treatments (SR2211, 5 mg/kg, i.p., 5 times a week; ENZ, 10 
mg/kg, oral, 5 times a week; or vehicle) on growth of C4-2B or 22Rv1 xenografts (n = 6 
mice per group). Treatment started when C4-2B tumors reached approximately100 mm3, or 
22Rv1 tumors reached approximately 50 mm3. Mean tumor volume ± s.e.m and 
representative tumor images are shown. Scale bar is 1cm. Significance was calculated using 
Student’s t-test with the following p values: for C4-2B exnografts, * p = 0.000293, ** p = 
6.67E-05, *** p=1.13E-05; for 22Rv1 xenografts, # p = 3.03E-08, ** p = 1.77E-09, *** p = 
1.14E-08.
(c) Immunoblotting (left) of C4-2B xenograft tumors after 24 days of treatment with vehicle 
or SR2211 as in (a). Cell lysate for each lane was from homogenized tumor tissues 
randomly combined from three mice of vehicle or SR2211 group. Anti-cleaved caspase-3 
IHC images of tumor sections were shown at right. Scale bar is 50 µm.
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(d) Schematics illustrating CRPC-VCaP xenograft tumor establishment and treatment (left). 
Castrated mice bearing the CRPC-VCaP xenografts (n = 6 mice per group) received vehicle, 
SR2211 (i.p.; 5 mg/kg), ENZ (oral; 10 mg/kg), or a combination of SR2211 and ENZ, as 
indicated, 5 times a week. Mean tumor volume ± s.e.m was shown. Significance was 
calculated using Student’s t-test. * p = 1.98E-10, ** p = 1.46E-10, *** p = 7.21E-13.
(e) Mice bearing VCaP xenografts as in (d) treated with vehicle, SR2211, ENZ or 
combination for 23 days were assessed for spontaneous metastasis to the femur (bone 
marrow) and liver. Genomic DNA isolated from these sites was analyzed for metastasized 
cells by measuring human Alu sequence (by Alu-qPCR).
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